Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next
The FDA issued an early alert on Abiomed Impella RP heart pumps, citing a pressure sensor defect linked to 22 serious injuries but no deaths. Johnson & Johnson shares rose 0.6% to $234.47, holding steady after hours. Traders await further FDA updates and MedTech data at the AF Symposium on Feb. 6. The S&P 500 fell 0.51% while the Dow gained 0.53%.
